GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Renovaro Inc.
Renovaro, a company developing cancer treatment technologies, is extremely volatile. Its price reflects not current revenues, but rather investors' faith in the potential of its scientific platform, its dependence on research news, and its funding needs.
Share prices of companies in the market segment - Cancer cure
Renovaro is a biotech company developing advanced cell and gene therapies for the treatment of cancer and infectious diseases. We've categorized it as a Cancer Treatment company. The chart below shows how investors view this high-risk but promising biotech segment.
Broad Market Index - GURU.Markets
Renovaro is a biotech company developing cutting-edge cell and gene therapies for the treatment of cancer and infectious diseases. As a component of the GURU.Markets index, it represents the high-risk but promising biotech segment. The chart below represents the entire market. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
RENB - Daily change in the company's share price Renovaro Inc.
For Renovaro Inc., an oncology company, daily price change is a measure of extreme volatility. It reflects investor reaction to clinical trial news and is a critical parameter in risk assessment formulas.
Daily change in the price of a set of shares in a market segment - Cancer cure
Renovaro Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with RENB's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Renovaro is a biotech company developing cancer treatments. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Renovaro Inc.
Renovaro Inc.'s year-to-date performance tells the story of its ambitious strategy to combine biotechnology and artificial intelligence. Its 12-month market cap reflects investors' belief that its gene therapy and AI research will lead to a new generation of treatments for cancer and other diseases.
Annual dynamics of market capitalization of the market segment - Cancer cure
Renovaro Inc. is a biopharmaceutical company developing innovative cancer treatments. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Renovaro is a highly speculative biotech company. Its stock price has nothing to do with fundamentals or the economy, but is driven by rumors, hype, and investor confidence in the potential of its developments, making it a high-risk bet on science.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Renovaro Inc.
Renovaro is a biotech company focused on oncology and AI. Its monthly performance reflects progress in its scientific developments and corporate actions. News about clinical trials and M&A transactions are the main drivers of significant price fluctuations.
Monthly dynamics of market capitalization of the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) works in cell and gene therapy for the treatment of cancer and infectious diseases. This segment of biotech is one of the riskiest and most potentially disruptive. The chart below reflects the roller coaster of investor sentiment regarding cutting-edge, yet often speculative, medical technologies.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Renovaro is a biotech company working in cell therapy and immuno-oncology. Its shares represent a venture bet on the success of its scientific developments. Its performance will be determined by lab news and clinical trial results, rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Renovaro Inc.
Renovaro Biosciences is a biotech company focused on innovative cancer treatments. Its weekly stock price is highly volatile, driven by news about clinical trials, research progress, and overall investor interest in its technology platform, which is typical for biotech.
Weekly dynamics of market capitalization of the market segment - Cancer cure
Renovaro Biosciences is a biotech company focused on innovative cancer treatments. Its weekly stock price is highly volatile, driven by news about clinical trials, research progress, and overall investor interest in its technology platform, which is typical for biotech.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Renovaro, a biotech company, live in a world of their own. Their performance is driven by clinical trial data. A chart comparing the stock to the S&P 500 clearly demonstrates how the stock can rise or fall, completely ignoring the broader market.
Market capitalization of the company, segment and market as a whole
RENB - Market capitalization of the company Renovaro Inc.
Renovaro's market capitalization is the story of the merger of a biotech company working on gene therapy for cancer and HIV with an AI company. The chart reflects the market's attempts to price this unusual synergy. Its speculative dynamics visualize how investors view this risky bet on the fusion of biotech and artificial intelligence.
RENB - Share of the company's market capitalization Renovaro Inc. within the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company focused on gene and cell therapies for the treatment of cancer and infectious diseases. Its share of its segment's market capitalization reflects investors' faith in its science. The chart below shows the high volatility associated with clinical development news.
Market capitalization of the market segment - Cancer cure
Renovaro Biosciences develops cutting-edge cancer treatments, including cell and gene therapies. The chart below shows the total market capitalization of the oncology sector, illustrating the enormous scale of investment and research efforts aimed at finding breakthrough treatments for this disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a glimpse of the hope for a universal cure for cancer. Renovaro Inc. (formerly Enochian BioSciences) is developing a gene-modified cell therapy that it believes could be effective against many types of cancer. Its highly volatile track record reflects both its bold claims and investor skepticism.
Book value capitalization of the company, segment and market as a whole
RENB - Book value capitalization of the company Renovaro Inc.
Renovaro's book value represents its capital, which is being transformed to develop cutting-edge cancer treatments based on AI and genetic engineering. This is scientific capital in the making. The chart shows the company's capital management history as it shifts its strategy to focus on breakthrough oncology technologies.
RENB - Share of the company's book capitalization Renovaro Inc. within the market segment - Cancer cure
Renovaro is a biotech company developing cutting-edge cancer treatments. Its assets include intellectual property and research data. The chart shows a minimal share of physical assets, typical for a company in the development stage.
Market segment balance sheet capitalization - Cancer cure
Biopharmaceuticals, as the BCap_Ges chart shows, are knowledge-intensive. Renovaro, focused on oncology and AI, is a prime example. Its capital is invested in research and technology, not manufacturing. It's a business at the intersection of two knowledge-intensive industries.
Book value of all companies included in the broad market index - GURU.Markets
Renovaro's assets comprise capital and a portfolio of developments in cell and gene therapies for cancer and HIV. Its book value provides the financial foundation for its research, which seeks to create a new generation of living, physical medicines to treat terminal diseases.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Renovaro Inc.
Renovaro is a company working at the intersection of AI and biotechnology for cancer treatment. It's a combination of two of the hottest topics. Its book value is minimal. Its market capitalization will reflect extreme speculative expectations. Its MvsBCap chart is a pure indicator of hype, driven by news from both the AI and biotech worlds.
Market to book capitalization ratio in a market segment - Cancer cure
Renovaro Biosciences (formerly Enochian BioSciences) works in cell and gene therapy for the treatment of cancer and infectious diseases. Its valuation is based on the potential of its scientific developments. The chart reflects investors' expectations for its future breakthroughs.
Market to book capitalization ratio for the market as a whole
Renovaro Biosciences (formerly Enochian BioSciences) is working on developing gene-modified cell therapies for the treatment of cancer and HIV. This is an extremely ambitious goal. Its market valuation reflects investors' faith in the breakthrough potential of its science. The chart shows the high premium the market places on technologies capable of defeating the most severe diseases.
Debts of the company, segment and market as a whole
RENB - Company debts Renovaro Inc.
Renovaro, a biotech company focused on oncology, is devoting its entire capital to research and development. Like most companies at this stage, it relies entirely on external funding to advance its projects. This chart reflects its financial strategy for survival and growth in the long and capital-intensive process of developing new cancer treatments.
Market segment debts - Cancer cure
Renovaro Inc. (formerly Renovaro Biosciences) works in the fields of advanced cancer treatments and AI. The combination of biotechnology and artificial intelligence is a highly capital-intensive field. This chart shows how the company funds its dual ambitions: developing innovative therapies and building sophisticated AI platforms.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Renovaro Inc.
Renovaro, a biotech company focused on fighting cancer, is entirely dependent on the success of its research. This chart shows how much it relies on debt to finance R&D. For a company at this stage, debt is both its lifeblood and a sword of Damocles if clinical trials don't meet investor expectations.
Market segment debt to market segment book capitalization - Cancer cure
Renovaro Inc. is a biotech company working on cutting-edge cancer and HIV treatments. The chart shows the sector's debt burden. It helps understand how the company finances its ambitious and high-risk research programs compared to other innovative companies in the fields of oncology and virology.
Debt to book value of all companies in the market
Renovaro Inc. (formerly Renovaro Biosciences) develops cutting-edge treatments for cancer and HIV. For a biotech company whose operations require colossal and long-term investments, the overall financial market situation, reflected in this chart, is critical. It determines the availability of capital for research and development.
P/E of the company, segment and market as a whole
P/E - Renovaro Inc.
For Renovaro, an oncology company, this chart reflects its hopes for a breakthrough in cancer treatment. Its valuation is based solely on investors' faith in the scientific potential of its developments, rather than on current financial performance, which is typical for early-stage biotech companies.
P/E of the market segment - Cancer cure
This chart shows the average P/E for the biotech sector in which Renovaro is developing. The industry's very high valuation reflects hopes for breakthroughs in cancer treatment. This metric provides a backdrop against which investors evaluate the scientific potential and risks associated with Renovaro's oncology portfolio.
P/E of the market as a whole
Renovaro Biosciences is developing cutting-edge treatments for cancer and HIV using cell and gene therapies. This is a high-risk field with the potential for revolutionary breakthroughs. This chart shows investors' risk appetite. It allows one to assess how the market perceives the company's ambitious goals and how its scientific data supports its current valuation compared to other biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Renovaro Inc.
Renovaro Inc. (formerly Renovaro Biosciences) is a biotech company developing cutting-edge treatments for cancer and HIV. Its valuation is a bet on scientific breakthroughs. This chart shows analysts' belief that its innovative approaches, including cell and gene therapies, will prove successful in the future.
%20P%2FE%20Renovaro%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Renovaro-Inc.&v=1772692331402 "Chart of the company's future (projected) P/E Renovaro Inc.")
Future (projected) P/E of the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company developing advanced treatments and diagnostics for cancer and infectious diseases. This chart displays its future profitability expectations, allowing us to assess how the market perceives its ambitious scientific goals and the potential of its technology platform.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Cancer-cure&v=1772692331456 "Future (projected) P/E graph of the market segment - Cancer cure")
Future (projected) P/E of the market as a whole
Renovaro Inc. is a biotech company specializing in cutting-edge cancer treatments. Like many companies in this sector, it depends on clinical trial results and the availability of funding. This chart, showing overall market sentiment, is an indicator of this availability. Investor optimism is helping Renovaro continue its research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772692331533 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Renovaro Inc.
Renovaro Inc. (formerly Enochian BioSciences) works in cell and gene therapies for cancer and HIV. Its financial picture is a story of significant investments in breakthrough scientific research. This chart shows the capital burn required to advance these complex and potentially revolutionary treatments through clinical trials.
Profit of companies in the market segment - Cancer cure
Renovaro Biosciences (formerly Enochian BioSciences) is working to develop innovative treatments and prevention methods for HIV, cancer, and other infectious diseases. This is a high-risk, high-reward field. This graph reflects the dynamics of biotechnology, where a scientific breakthrough in treating global diseases can generate billions in revenue.
Overall market profit
Renovaro Inc. (formerly Enochian BioSciences) works in gene therapy and immunology. Like any company at the forefront of science, access to capital is critical. This chart, reflecting investor sentiment, influences their willingness to fund bold scientific hypotheses with potentially enormous, but distant, returns.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Renovaro Inc.
Renovaro Inc. is a biotechnology company focused on developing advanced cancer treatments, including cell therapy and genetic engineering. Its future depends on clinical success. This chart represents a consolidated analyst forecast, reflecting the company's scientific potential and its ability to bring products to market.
%20profit%20of%20the%20company%20Renovaro%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Renovaro-Inc.&v=1772692331703 "Graph of future (projected) profit of the company Renovaro Inc.")
Future (predicted) profit of companies in the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company developing innovative treatments for cancer and infectious diseases. Its research encompasses cell and gene therapy. This chart shows profitability forecasts for the biotech sector, providing insight into the overall investment climate in advanced biomedical research.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Cancer-cure&v=1772692331747 "Graph of future (predicted) profits of companies in a market segment - Cancer cure")
Future (predicted) profit of the market as a whole
Renovaro Inc. (formerly Renovaro Biosciences) develops cancer treatments. As a biotech company, it is dependent on funding and investor sentiment. This chart, reflecting general economic expectations, influences investor risk appetite, which drives capital inflows into companies engaged in long-term scientific research.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772692331755 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Renovaro Inc.
Renovaro Inc. is developing cutting-edge cancer treatments. For an early-stage biotech company, this chart is a measure of hope. Market value reflects not current revenue, but the potential value of its innovative therapy if clinical trials are successful.
P/S market segment - Cancer cure
Renovaro Inc. is a biotechnology company developing advanced cancer and HIV treatments. This chart displays the average revenue estimate for the biotechnology sector. It provides insight into how investors value the potential revenue from Renovaro's innovative therapeutic approaches to combating serious diseases.
P/S of the market as a whole
Renovaro Biosciences develops cutting-edge cell therapies for cancer and HIV. Their research targets some of the most complex medical challenges. This chart provides a general revenue metric against which to judge how highly investors value biotech companies with potentially revolutionary drugs.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Renovaro Inc.
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company focused on developing gene and cell therapies for the treatment of cancer and infectious diseases. This chart reflects investor expectations for its scientific developments. The valuation is based on the potential of its technologies to offer breakthrough treatments in the future.
%20P%2FS%20Renovaro%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Renovaro-Inc.&v=1772692331835 "The graph of the company's future (projected) P/S Renovaro Inc.")
Future (projected) P/S of the market segment - Cancer cure
Renovaro Inc. is a biotechnology company specializing in the development of advanced cell and gene therapies for the treatment of cancer and infectious diseases such as HIV. This chart shows how the market views its innovative approaches compared to the highly competitive oncology and gene therapy sector.
%20P%2FS%20market%20segment%20graph%20-%20Cancer%20cure&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Cancer-cure&v=1772692331876 "Future (projected) P/S market segment graph - Cancer cure")
Future (projected) P/S of the market as a whole
Renovaro is a biotech company developing cancer treatments. Like many companies in this field, its value is based on expectations of future success. This graph, reflecting investors' overall risk appetite, directly impacts Renovaro's ability to raise capital. Market optimism is essential for funding long-term oncology research.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772692331900 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Renovaro Inc.
Renovaro Inc. is a biotechnology company focused on developing cutting-edge cancer treatments using cell and gene therapies. This chart reflects its financial flows, which at this stage likely come from research funding rather than commercial sales. It illustrates investments in breakthrough oncology technologies.
Sales of companies in the market segment - Cancer cure
Renovaro Inc. is a leading biotechnology company specializing in the development of cell and gene therapies for the treatment of cancer and other diseases. Its business is segmented by various research platforms and therapeutic candidates. This chart reflects the financial flows associated with one of its key innovative oncology areas.
Overall market sales
Renovaro Inc. is a biotechnology company developing cutting-edge treatments for cancer and HIV. Its value is determined by scientific potential and progress in clinical development. The company strives for breakthroughs in the most complex areas of medicine, and its success has the potential to transform the lives of patients, creating enormous social and economic value.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Renovaro Inc.
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company developing gene and cell therapies for the treatment of cancer and infectious diseases such as HIV and hepatitis B. The company's future sales projections are a bet on the success of its advanced and potentially revolutionary therapeutic approaches.
%20sales%20of%20the%20company%20Renovaro%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Renovaro-Inc.&v=1772692332032 "Schedule of future (projected) sales of the company Renovaro Inc.")
Future (projected) sales of companies in the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company developing gene and cell therapies for the treatment of cancer and infectious diseases. This chart shows expectations for the entire oncology sector. It helps assess the progress in advanced treatments and the investment interest analysts are predicting for the entire industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Cancer-cure&v=1772692332049 "Schedule of future (projected) sales of companies in the market segment - Cancer cure")
Future (projected) sales of the market as a whole
Renovaro Inc., a company developing cutting-edge cancer treatments, like many development-stage biotech companies, relies on external funding. This chart of overall sales forecasts reflects the overall market sentiment, which influences investor willingness to invest in high-risk scientific projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772692332065 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Renovaro Inc.
Renovaro Inc. (formerly Renovaro Biosciences) is a biotechnology company focused on developing advanced cancer treatments, including cell and gene therapies. This chart reflects its financial performance at the R&D stage, where significant investments in science are key to the development of future breakthrough cancer treatments.
Market segment marginality - Cancer cure
Renovaro is a biotech company working on cutting-edge treatments for cancer and HIV. For a company engaged in breakthrough but risky research, operational efficiency lies in maximizing capital efficiency. The chart shows how the company manages its resources in the race to develop new treatments.
Market marginality as a whole
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company developing innovative treatments for cancer and infectious diseases. Its future depends on the success of its scientific developments. This chart shows the profitability of mature businesses, while RENB's value lies in the potential of its scientific platform to offer breakthrough treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Renovaro Inc.
Renovaro Biosciences is developing cutting-edge cancer treatments using cell and gene therapy. This graph shows a small but highly specialized team of scientists. For a biotech company at the forefront of science, the team's size reflects the current phase of research and development in their complex scientific journey.
Share of the company's employees Renovaro Inc. within the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) develops innovative treatments for cancer and infectious diseases. Its ambitious scientific projects require a team of talented researchers. This chart reflects its investment in human capital to solve the most complex medical problems.
Number of employees in the market segment - Cancer cure
Renovaro Biosciences (formerly Enochian BioSciences) develops cell and gene therapies for the treatment of cancer and infectious diseases. This chart reflects employment in the oncology sector. The growing number of scientists in this field indicates significant investment and scientific advancement, creating a highly competitive but potentially disruptive environment for Renovaro.
Number of employees in the market as a whole
Renovaro Inc. (formerly Renovaro Biosciences) is a biotech company focused on oncology and AI. For the company, the overall economic situation, as reflected in the chart, is less important than scientific breakthroughs and funding. Research success is the primary driver for hiring top talent.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Renovaro Inc. (RENB)
Renovaro Inc. (formerly Enochian BioSciences) is a biotech company focused on gene therapy and oncology. This chart likely shows a very high market cap per employee. This is typical for early-stage biotech, where the entire value is derived from the market valuation of scientific potential and intellectual property.
%20of%20the%20company%20Renovaro%20Inc.%20(RENB)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Renovaro-Inc.-RENB&v=1772692332385 "Chart of market capitalization per employee (in thousands of dollars) of the company Renovaro Inc. (RENB)")
Market capitalization per employee (in thousands of dollars) in the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotech company working on treatments and prevention for HIV, hepatitis, and cancer. In biopharma, especially in the early stages, market value per employee is almost a pure valuation of scientific potential and intellectual property. It reflects investors' expectations for future breakthroughs.
%20by%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Cancer-cure&v=1772692332414 "Market capitalization per employee (in thousands of dollars) by market segment - Cancer cure")
Market capitalization per employee (in thousands of dollars) for the overall market
Renovaro Inc. (formerly Enochian BioSciences) is a biotechnology company focused on developing gene-modified cell therapies for the treatment and prevention of cancer. The chart illustrates the high, albeit speculative, valuation the market places on cutting-edge scientific research in oncology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772692332437 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Renovaro Inc. (RENB)
Renovaro Inc. (formerly Enochian Bio) is a biotech company focused on developing treatments for cancer and infectious diseases (HIV, hepatitis B). It is an early-stage R&D company. This negative graph shows how much capital is invested in each scientist working on these complex and potentially breakthrough, but currently unprofitable, treatments.
%20Chart%20Renovaro%20Inc.%20(RENB)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Renovaro-Inc.-RENB&v=1772692332459 "Company Profit Per Employee (in thousands of dollars) Chart Renovaro Inc. (RENB)")
Profit per employee (in thousands of dollars) in the market segment - Cancer cure
Renovaro Inc. (formerly Enochian BioSciences) is a biotech company working on treatments and prevention for HIV and cancer. In this field, the effectiveness of the scientific team is measured by research progress. This metric reflects how investments in personnel translate into company development, which can be compared with the biotech industry average.
%20in%20the%20market%20segment%20-%20Cancer%20cure&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Cancer-cure&v=1772692332468 "Chart of profit per employee (in thousands of dollars) in the market segment - Cancer cure")
Profit per employee (in thousands of dollars) for the market as a whole
Renovaro (RENB) is a biotech company working in cell therapy and oncology. It is a clinical-stage R&D company. Negative profit per employee is the norm. The chart shows the "cost" of the team of scientists working on this complex technological platform, which does not yet generate revenue.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772692332480 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Renovaro Inc. (RENB)
Renovaro is a biotech company focused on oncology. While still in the research stage, its revenue may be minimal or nonexistent. This timeline will indicate whether its scientific platform can lead to commercially successful drugs.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Renovaro-Inc.-RENB&v=1772692332507 "Sales chart per company employee Renovaro Inc. (RENB)")
Sales per employee in the market segment - Cancer cure
Renovaro (formerly Enochian Bio) is a biotech company working on advanced treatments for cancer and infectious diseases, including cell and gene therapies. This chart compares their revenue per employee (R&D) to the industry average, reflecting the effectiveness of their scientific platform on the path to commercialization.
Sales per employee for the market as a whole
Renovaro Inc. (formerly Enochian Bio) is a biotechnology company focused on advanced treatments for cancer and infectious diseases (AIDS) using cell and genetic engineering. It is an early-stage R&D company with no commercial revenue. This graph will reflect $0, as all employees are scientists engaged in research.
Short shares by company, segment and market as a whole
Shares shorted by company Renovaro Inc. (RENB)
Renovaro (RENB) is a biotech company working on cancer and possibly HIV treatments. The company's shares are extremely volatile and often move based on news rather than fundamental data. This chart shows the number of investors who consider the company a speculative "dummy" and are betting that its science has no real value.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Renovaro-Inc.-RENB&v=1772692332526 "Short Shares Chart for the Company Renovaro Inc. (RENB)")
Shares shorted by market segment - Cancer cure
Renovaro (formerly Enochian Bio) is a biotech company working on genetically engineered treatments for cancer and infectious diseases. This chart shows the odds against the early-stage biotech sector. It reflects the general pessimism of investors and the high probability of clinical trial failure for this type of company.
Shares shorted by the overall market
Renovaro (RENB) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Renovaro Inc. (RENB)
Renovaro Inc. (formerly Enochian Bio) is a biotech company focused on gene therapy and immunology for the treatment of cancer and HIV. The company's shares are extremely volatile. This oscillator measures investor "fever": any hint of success in trials can trigger "overheating" (above 70), while failure can lead to deep "oversold" (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Renovaro-Inc.-RENB&v=1772692332547 "RSI 14 indicator chart for the company's stock Renovaro Inc. (RENB)")
RSI 14 Market Segment - Cancer cure
Renovaro Inc. (formerly Enochian Bio) is a biotech company working on cell and gene therapies for the treatment of cancer and infectious diseases such as HIV. This chart measures the collective excitement in the oncology biotech sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
For Renovaro, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast RENB (Renovaro Inc.)
Renovaro (formerly Enochian Bio) is a biotech company focused on developing cell and gene therapies, including for the treatment of cancer and HIV. This chart shows the average target price. Analysts' forecasts are based on an assessment of its preclinical pipeline and the potential of its technology platforms.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-RENB-Renovaro-Inc.&v=1772692332585 "A chart showing analyst consensus forecasts for the expected stock price. RENB (Renovaro Inc.)")
The difference between the consensus estimate and the actual stock price RENB (Renovaro Inc.)
Renovaro (formerly Enochian) is a biotech company developing cell and gene therapies for cancer and HIV. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their view of this highly ambitious and risky R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-RENB-Renovaro-Inc.&v=1772692332589 "A chart showing the difference between the consensus forecast and the actual stock price. RENB (Renovaro Inc.)")
Analyst consensus forecast for stock prices by market segment - Cancer cure
Renovaro (formerly Enochian Bio) is a biotech company developing therapies for the treatment and prevention of cancer (including advanced cell therapy). This chart shows the overall analyst expectations for the oncology sector. It reflects whether experts believe this risky R&D platform will succeed.
Analysts' consensus forecast for the overall market share price
Renovaro is a biotech company specializing in the development of immunotherapies (cell therapies) and vaccines for cancer treatment using an AI platform. This chart shows the overall market "risk appetite." For Renovaro, a high-risk clinical-stage company, overall market optimism (risk appetite) is critical to attracting the capital needed to fund R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Renovaro Inc.
Renovaro is a biotech company attempting to reinvent itself by combining AI analytics with R&D in the field of immuno-oncology (cancer vaccines). This chart is a clear indicator of confidence in their new R&D strategy. It reflects a speculative assessment of their scientific progress, clinical trial data, and chances of approval.
AKIMA Market Segment Index - Cancer cure
Renovaro Inc. (RENB) is a biotech company focused on advanced cancer treatments, including cell therapy and immunotherapy, often combined with AI platforms. The chart shows the segment's average index, helping investors assess how this high-tech approach to oncology compares to the average risk in the drug development sector.
The AKIM Index for the overall market
Renovaro is a biotech company using AI for early cancer diagnosis and immunotherapy development. It has merged with GEDi Cube. This chart, reflecting the market average, is just a backdrop. It helps assess how this speculative story at the intersection of AI and biotech fits into the context of overall macroeconomic trends.
